Long‐Term Correction of Murine Glycogen Storage Disease Type III by AAV‐Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial PullulanaseKuo An Liao(Duke University), Baodong Sun(Duke University)Advances in Cell and Gene TherapyJanuary 1, 202510.1155/acg2/4639392Cited by 1SaveCiteExport RISWatch citationsRelated PapersSuppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice|JCI Insight|2022|14